Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): A double-blind, randomised, placebo-controlled clinical trial

The Lancet

Volumn 387, Issue 10037, 2016, Pages 2507-2520

  Anthenelli, Robert M ^a   Benowitz, Neal L ^b   West, Robert ^c   St Aubin, Lisa ^d   McRae, Thomas ^d   Lawrence, David ^d   Ascher, John ^e   Russ, Cristina ^d   Krishen, Alok ^f   Evins, A Eden ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d PFIZER INC   (United States)

^e GLAXOSMITHKLINE   (United States)

^f PAREXEL INTERNATIONAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE PATCH; PLACEBO; VARENICLINE; DOPAMINE UPTAKE INHIBITOR; NICOTINE GUM; NICOTINIC AGENT;

ADULT; ARTICLE; ATTRIBUTABLE RISK; COHORT ANALYSIS; CONTROLLED STUDY; COUNSELING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HEALTH CENTER; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; OUTPATIENT DEPARTMENT; PERSONNEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING; SMOKING CESSATION; ADOLESCENT; AGED; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; PREVENTION AND CONTROL; PROCEDURES; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BUPROPION; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NICOTINIC AGONISTS; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME; VARENICLINE; YOUNG ADULT;

EID: 84964258009     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30272-0     Document Type: Article

References (30)

1. K Cahill, S Stevens, R Perera, T Lancaster Pharmacological interventions for smoking cessation: an overview and network meta-analysis Cochrane Database Syst Rev 5 2013 CD009329.
2. Institute for Safe Medication Practices Quarter watch: monitoring FDA MedWatch reports. Sept 24, 2014. Data from 2013 Quarters 2 and 3 http://www.ismp.org/quarterwatch/pdfs/2013Q3.pdf 2014 (accessed Sept 8, 2015).
3. US Food and Drug Administration Food and Drug Administration briefing document. Joint meeting of the Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee, Oct 16, 2014, Chantix and Serious Neuropsychiatric Adverse Events http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM418705 2014 (accessed Sept 9, 2015).
4. MC Fiore, CR Jaen, TB Baker et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2008. US Department of Health and Human Services, Public Health Service www.surgeongeneral.gov/initiatives/tobacco/index.html (accessed Sept 30, 2015).
5. AL Smith, SM Carter, S Chapman, SM Dunlop, B Freeman Why do smokers try to quit without medication or counselling? A qualitative study with ex-smokers BMJ Open 5 2015 e007301
6. R Freedman Exacerbation of schizophrenia by varenicline Am J Psychiatry 164 2007 1269
7. MK Yousefi, TD Folsom, SH Fatemi A review of varenicline's efficacy and tolerability in smoking cessation studies in subjects with schizophrenia J Addict Res Ther 2011 S4
8. US Food and Drug Administration FDA drug safety newsletter, volume 2, number 1, 2009 http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm107311.htm 2009 (accessed Sept 8, 2015).
9. B Pasternak, H Svanström, A Hviid Use of varenicline versus bupropion and risk of psychiatric adverse events Addiction 108 2013 1336 1343
10. RM Anthenelli, C Morris, TS Ramey et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial Ann Intern Med 159 2013 390 400
11. AE Evins, C Cather, SA Pratt et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial JAMA 311 2014 145 154
12. RD Gibbons, JJ Mann Varenicline, smoking cessation, and neuropsychiatric adverse events Am J Psychiatry 170 2013 1460 1467
13. KH Thomas, RM Martin, DW Knipe, JP Higgins, D Gunnell Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis BMJ 350 2015 h1109
14. JR Hughes, LF Stead, J Hartmann-Boyce, K Cahill, T Lancaster Antidepressants for smoking cessation Cochrane Database Syst Rev 1 2014 CD000031
15. Y Molero, P Lichtenstein, J Zetterqvist, CH Gumpert, S Fazel Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study BMJ 350 2015 h2388
16. KH Thomas, RM Martin, NM Davies, C Metcalfe, F Windmeijer, D Gunnell Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study BMJ 347 2013 f5704
17. TB Baker, ME Piper, JH Stein et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a randomized clinical trial JAMA 315 2016 371 379
18. American Psychiatric Association Diagnostic and statistical manual of mental disorders, 4th edn, text revision http://dsm.psychiatryonline.org/doi/abs/10.1176/appi.books.9780890420249.dsm-iv-tr 2000 (accessed Oct 8, 2015).
19. A Osman, CL Bagge, PM Gutierrez, LC Konick, BA Kopper, FX Barrios The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples Assessment 8 2001 443 454
20. K Posner, GK Brown, B Stanley et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults Am J Psychiatry 168 2011 1266 1277
21. World Medical Association World Medical Association Declaration of Helsinki - ethical principles for medical research involving human subjects http://www.wma.net/en/30publications/10policies/b3/17c.pdf 2008 (accessed Oct 8, 2015).
22. International Conference on Harmonisation Guideline for good clinical practice E6(R1) http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/good-clinical-practice.html 1996 (accessed Oct 8, 2015).
23. MB First, RL Spitzer, M Gibbon, JBW Williams Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition (SCID-I/P) 2002 Biometrics Research, New York State Psychiatric Institute; November New York
24. M First, M Gibbon, RL Spitzer, JBW Williams, LS Benjamin Structured clinical interview for DSM-IV axis II personality disorders (SCID-II) 1997 American Psychiatric Press Washington, DC
25. AS Zigmond, RP Snaith The hospital anxiety and depression scale Acta Psychiatr Scand 67 1983 361 370
26. K Fagerström Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence Nicotine Tob Res 14 2012 75 78
27. JR Hughes, JP Keely, RS Niaura, DJ Ossip-Klein, RL Richmond, GE Swan Measures of abstinence in clinical trials: issues and recommendations Nicotine Tob Res 5 2003 13 25
28. S Tonstad, S Davies, M Flammer, C Russ, J Hughes Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis Drug Saf 33 2010 289 301
29. D Kotz, W Viechtbauer, C Simpson, OC van Schayck, R West, A Sheikh Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study Lancet Respir Med 3 2015 761 768
30. PM Cinciripini, JD Robinson, M Karam-Hage et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal JAMA Psychiatry 70 2013 522 533